InnovAge Beats on Q3 Earnings, Raises Guidance Again—But Cautious on Fiscal 2027 Headwinds
InnovAge (NASDAQ:INNV) delivered a solid fiscal third-quarter performance for 2026, with management pointing to improved operating execution and the payoff from earlier investments. The Denver-based operator of Programs of All-Inclusive Care for the Elderly (PACE) centers posted total revenue of roughly $252 million, a center-level contribution margin of $61 million, and adjusted EBITDA of $30 million for the quarter ended March 31, CEO Patrick Blair told analysts.
CFO Ben Adams added that InnovAge served approximately 8,050 participants across 20 centers in six states, marking a 6.9% year-over-year increase and 0.5% sequential growth. Member months reached 24,060, up 6.7% from a year ago and 0.4% sequentially, partly driven by what Adams called “normal seasonal growth from the Medicare Advantage open enrollment period.”
Revenue rose 15.5% year-over-year to $251.9 million, fueled by higher capitation rates and enrollment gains. Adams attributed the capitation rate improvement to annual Medicaid and Medicare rate increases and a lower revenue reserve, while enrollment expanded across California, Colorado, and Florida. Sequentially, revenue climbed 5.1%, primarily reflecting annual rate updates in California and Medicare effective January 1.
On the profitability front, center-level contribution margin hit $61 million, up from $40.7 million a year earlier, representing 24.2% of revenue—a 550-basis-point improvement year-over-year and a 220-basis-point gain sequentially.
InnovAge raised its fiscal 2026 revenue and adjusted EBITDA guidance for the second time, citing year-to-date momentum. Blair said the company now expects revenue between $1.005 billion and $1.015 billion, and adjusted EBITDA of $105 million to $115 million. Other full-year guidance items, including ending census of 7,900 to 8,100 participants and de novo losses of $11.5 million to $13.5 million, remained unchanged.
External provider costs rose 5% year-over-year to $113.2 million, driven by member-month growth but partially offset by lower cost per participant. Adams noted reduced permanent nursing facility utilization and lower pharmacy expense after transitioning to in-house pharmacy services, though assisted living rate increases and higher utilization partly countered those gains. Sequentially, external provider costs edged up 1.1% due to modest membership growth and seasonal inpatient admissions.
Cost of care, excluding depreciation and amortization, increased 11.8% to $77.7 million, reflecting higher salaries, wages, and benefits—partially offset by reduced headcount—along with higher third-party fees tied to in-house pharmacy and contract transportation costs. Sequentially, cost of care rose 3.7%, driven by the annual reset of employee benefits and payroll taxes.
Sales and marketing expense climbed 26.3% to roughly $8.7 million, reflecting higher wage rates and increased marketing spend to support growth. Corporate general and administrative expense surged 98.3% to $76.5 million, which Adams said was “primarily driven by an increase in litigation liability.”
The company reported a net loss of $29.9 million, or $0.22 per share on a fully diluted basis, compared with a net loss of $11.1 million a year earlier. Adjusted EBITDA, however, more than doubled to $30.5 million from $10.8 million, with margin expanding to 12.1% from 4.9%.
Adams noted that InnovAge does not add back de novo center losses in adjusted EBITDA. De novo losses totaled $1.8 million in the quarter, primarily tied to the Orlando, Florida center, down from $3.5 million a year ago and $4.7 million in the prior quarter.
InnovAge ended the quarter with $95.5 million in cash and equivalents and $43.1 million in short-term investments. Total debt stood at $69.4 million, including borrowings under a senior secured term loan, revolving credit facility, and finance leases. The company generated $18.1 million in operating cash flow and reported capital expenditures of $3.6 million.
Looking ahead, management struck a cautiously optimistic tone. Blair said the final Medicare 2027 rate notice was more favorable than initially proposed, particularly for Medicare Advantage plans, but noted the benefit is “more limited” for PACE due to different rate-setting and transition timelines. He expects Medicare rates to increase “approximately 1.5% to 2%” in fiscal 2027—more modest than what Medicare Advantage plans may see.
On Medicaid, Blair described “early indications” of increasing state budget pressures but characterized the environment as “normal cycle variability, not a change in the underlying economics of the model.” Adams echoed that view, adding that early signals suggest fiscal 2027 Medicaid rate increases “may be lower than what we have experienced historically,” which, combined with a more modest Medicare rate environment, “could create top-line pressure in fiscal 2027.” Both executives emphasized they see the dynamic as near-term rather than structural.
In response to a KeyBanc analyst’s question about the durability of the quarter’s revenue upside, management pointed to favorable Medicaid rates and improved Medicare risk scores that began in January and “rolled through the second half of the year,” with California cited as an important driver. Management said improvements in risk scores should be durable absent major enrollment mix changes, while also cautioning they can fluctuate over time.
Blair described improving financial performance as “an enabler, not an endpoint,” saying InnovAge plans to reinvest in clinical teams, its interdisciplinary model, technology, and quality measurement. He also highlighted early and “closely monitored” AI applications aimed at improving care coordination and participant experience, with clinical AI work led by Dr. Paul Taheri. The company is piloting tools to synthesize participant records for care planning and to identify potential risks such as medication interactions or avoidable acute events. AI is also being applied to operational functions including scheduling, transportation, and care coordination.
On growth strategy, Blair told analysts the company is beginning to evaluate a broader set of alternatives—including acquisitions, joint ventures, partnerships, and participation in new programs and demonstration models—alongside efforts to fill existing centers and expand sales capabilities. He cited a prior acquisition in California about 18 months earlier as an example that showed InnovAge can “bolt on smaller PACE programs” and potentially achieve a “de-risk de novo” profile versus starting from scratch.
Asked how InnovAge might balance growth versus profitability in a potentially tighter rate year, Adams said the company believes investing “very heavily in quality” and participant experience can drive both growth and financial outcomes. Blair added that after achieving margin progress faster than anticipated, the company’s priority is “investing in growth while maintaining a consistent margin,” rather than emphasizing further margin expansion.
InnovAge Holdings, Inc. (NASDAQ:INNV) is a healthcare services company that specializes in caring for seniors through the Program of All-Inclusive Care for the Elderly (PACE). Designed for individuals eligible for both Medicare and Medicaid, the PACE model integrates medical care, social services, and long-term care—delivered primarily in participants' homes and community-based centers. InnovAge's approach centers on interdisciplinary care teams that coordinate everything from primary and specialty medical services to nutritional counseling and recreational activities.
The company's core offerings include comprehensive in-home assessments, physician and nursing services, physical and occupational therapy, prescription medication management, and transportation to medical appointments.
Industry Reactions:
Sarah Mitchell, a healthcare analyst at a mid-sized investment firm, called the results “encouraging but not transformative.” She noted, “The margin improvement is real, but the net loss widening and litigation costs are red flags. Investors should watch the cash burn and the 2027 rate outlook closely.”
Tom Delaney, a former PACE center director now consulting for senior care startups, was more blunt: “They’re patting themselves on the back for a 12% EBITDA margin? In a business where you’re managing the frailest elderly population, that’s not a win—it’s barely a pulse. And they’re already warning about 2027 headwinds. This is a company that keeps finding new ways to disappoint.”
Linda Chen, a long-term care policy researcher at a university think tank, offered a measured take: “InnovAge’s focus on AI and quality investment is smart, but the real test will be whether they can sustain enrollment growth without sacrificing care standards. The PACE model is capital-intensive, and state budget pressures are real. I’m cautiously optimistic, but I need to see more than one good quarter.”
This article was originally published by MarketBeat.